Suchergebnisse - "Rimassa, Lorenza"

PubPharm (370)

1

Letter : Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma

enthalten in: Alimentary pharmacology & therapeutics | 2024

von De Toni, E. | Mayerle, J. | Oehrle, B. | +5

2

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence : PURITY study

enthalten in: BMC cancer | 2024

von Niger, M. | Nichetti, F. | Fornaro, L. | +34

3

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

enthalten in: BMC cancer | 2024

von Niger, M. | Nichetti, F. | Fornaro, L. | +34

4

Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

enthalten in: Targeted oncology | 2024

von Rimini, M. | Loi, E. | Rizzato, M. | +26

5

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

6

Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer : Results of a propensity-matched analysis of the OnCovid registry

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2024

von Mostaghim, A. | Minkove, S. | Aguilar-Company, J. | +43

7

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

enthalten in: Journal of hepatology | 2024

von Celsa, C. | Cabibbo, G. | Fulgenzi, C. | +69

8

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Sangro, B. | Chan, S. | Kelley, R. | +123

9

Multidisciplinary treatment of hepatocellular carcinoma in 2023 : Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part II - Non-surgical treatments

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2024

von Cabibbo, G. | Daniele, B. | Borzio, M. | +22

10

Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

enthalten in: Targeted oncology | 2024

von Rimini, M. | Loi, E. | Rizzato, M. | +26

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[37]